KYPROLIS Amgen Australia Pty Ltd
Product name
KYPROLIS
Sponsor
Accepted date
Aug-2021
Active ingredients
carfilzomib
Proposed indication
For the treatment of relapsed or refractory multiple myeloma in combination with daratumumab and dexamethasone.
Application type
C (new medicine)
Publication date
Aug-21